Blog
Demystifying Pediatric Clinical Research for Emerging Biotech
A substantial change to the drug development landscape is currently underway. Regulatory authorities are starting to acknowledge pediatrics as one of…
Featured Insights
Ask the Experts: Understanding Juvenile Idiopathic Arthritis
In light of JIA Awareness Month, its treatments, its stigma, and more, we spoke with Dr. Johnny Peppers, Executive Director of Drug Development for…
PRA Teams with Microsoft to Enhance COVID-19 Monitoring
Over the past several months, participants in PRA Health Sciences’ Health Harmony COVID-19 Monitoring Program have had vital information about…
All Insights
Blog
Case Study
Leveraging Immuno-Oncology Real World Data to Amend Non-Small Cell Lung Cancer Study Design
Learn more about how PRA worked with a sponsor to create higher enrollment rates and more extensive country selection. Discover how they did this by…
Newsletter
Industry Watch
As we work our way through October and deeper into autumn, there have been many recent developments in healthcare and clinical research. There’s a…
Blog
CRISPR Technology Offers New Hope for Patients with Devastating Diseases
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a powerful new gene-editing tool with unprecedented implications for the future…
Blog
Ask the Experts: What Role Does Statistical Analysis Play in Clinical Research? (Part 1)
With our expertise and experience, we know the important roles that data and statistics play in clinical research and indeed healthcare. To give…
Newsletter
Rare Diseases Newsletter
This quarterly publication strives to keep you up to date on PRA’s Center for Rare Diseases initiatives and activities. Interested in learning more…
Newsletter
Industry Watch
As we move into the final quarter of 2020, we bring you news of the discovery of a rare genetic form of dementia known as Vacuolar Tauopathy. From…
Blog
5 Questions Small Biotech Should Ask Their Rare Disease Development Partner
Rare disease is a complicated but rewarding space for drug developers of all sizes. Most rare diseases have no approved treatment options, making…
Publication
Successful Adaptation to the Evolution of Complex Dose Escalation Within a Large Master Protocol Basket Design Across IO Co-Therapies
A case study describing a Phase I dose escalation and cohort expansion study of an immune checkpoint inhibitor in patients with advanced solid…
Case Study
Successes in Phase II Autologous Cellular Therapy Oncology Program
A case study describing two Phase II, multicenter studies assessing the efficacy and safety of an autologous cellular therapy treatment.